Merck & Co., Inc. Derivative Asset, Fair Value, Gross Asset
Merck & Co., Inc. (MRK) had Derivative Asset, Fair Value, Gross Asset of $569.00 million as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Notes › Offsetting › Derivative Asset, Subject to Master Netting Arrangement, after Offset and Deduction › Derivative Asset, Subject to Master Netting Arrangement, after Offset
us-gaap:DerivativeFairValueOfDerivativeAsset · last filed 2026-08-07
- 2026-06-30: Derivative Asset, Fair Value, Gross Asset $569.00M.
- 2026-03-31: Derivative Asset, Fair Value, Gross Asset $562.00M.
- 2025-12-31: Derivative Asset, Fair Value, Gross Asset $323.00M.
- 2025-09-30: Derivative Asset, Fair Value, Gross Asset $316.00M.
| Period end | Derivative Asset, Fair Value, Gross Asset |
|---|---|
| 2026-06-30 | $569.00M 10-Q · filed 2026-08-07 |
| 2026-03-31 | $562.00M 10-Q · filed 2026-05-04 |
| 2025-12-31 | $323.00M 10-Q · filed 2026-08-07 |
| 2025-09-30 | $316.00M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $546.00M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $410.00M 10-Q · filed 2025-05-02 |
| 2024-12-31 | $729.00M 10-K · filed 2026-02-24 |
| 2024-09-30 | $340.00M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $491.00M 10-Q · filed 2024-08-05 |
| 2024-03-31 | $357.00M 10-Q · filed 2024-05-03 |
| 2023-12-31 | $342.00M 10-K · filed 2025-02-25 |
| 2023-09-30 | $601.00M 10-Q · filed 2023-11-03 |
| 2022-12-31 | $433.00M 10-K · filed 2024-02-26 |
| 2015-06-30 | $1.63B 10-Q · filed 2015-08-06 |
| 2015-03-31 | $2.10B 10-Q · filed 2015-05-07 |
| 2014-12-31 | $1.85B 10-Q · filed 2015-08-06 |
| 2014-09-30 | $1.36B 10-Q · filed 2014-11-10 |
| 2014-06-30 | $742.00M 10-Q · filed 2014-08-07 |
| 2014-03-31 | $877.00M 10-Q · filed 2014-05-08 |
| 2013-12-31 | $1.09B 10-K · filed 2015-02-27 |
| 2013-09-30 | $951.00M 10-Q · filed 2013-11-07 |
| 2013-06-30 | $1.29B 10-Q · filed 2013-08-07 |
| 2013-03-31 | $1.31B 10-Q · filed 2013-05-09 |
| 2012-12-31 | $731.00M 10-K · filed 2014-02-27 |
| 2012-09-30 | $586.00M 10-Q · filed 2012-11-09 |
| 2012-06-30 | $884.00M 10-Q · filed 2012-08-07 |
| 2012-03-31 | $693.00M 10-Q · filed 2012-05-08 |
| 2011-12-31 | $755.00M 10-K · filed 2013-02-28 |
| 2011-09-30 | $864.00M 10-Q · filed 2011-11-08 |
| 2011-06-30 | $557.00M 10-Q · filed 2011-08-08 |
| 2010-12-31 | $628.00M 10-K · filed 2012-02-28 |
| 2010-09-30 | $469.30M 10-Q · filed 2010-11-08 |
| 2010-06-30 | $803.10M 10-Q · filed 2010-08-06 |
| 2009-12-31 | $378.90M 10-Q · filed 2010-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |